‘Big Tobacco’ Moment for Cannabis: What Insurers Need to Know About Murray V. Cresco

Why It Matters

The case could create unprecedented, multi‑state exposure for cannabis insurers, turning marketing conduct into a core underwriting risk. Its RICO component means any verdict could be multiplied, threatening the financial viability of existing policies.

Key Takeaways

• Murray v. Cresco alleges deceptive health claims across 12 states
• RICO claim could triple damages, exposing insurers to massive liability
• Policies may exclude coverage for marketing‑related claims and treble damages
• Underwriters must audit health claims, warnings, and scientific support
• Rescheduling cannabis to Schedule III raises expectations for product safety labeling

Pulse Analysis

The Murray v. Cresco class action marks a watershed moment for the U.S. cannabis industry, bringing a 320‑page complaint that accuses the nation’s largest MSOs of knowingly misrepresenting health benefits while downplaying serious mental‑health and cardiovascular risks. By invoking the federal RICO statute, plaintiffs aim to secure treble damages, a tactic reminiscent of the 1990s Big Tobacco battles. The lawsuit spans twelve states, coupling federal racketeering allegations with a suite of state consumer‑protection, warranty and negligent‑misrepresentation claims, thereby creating a multi‑jurisdictional exposure that could reshape how cannabis companies are held accountable for their marketing practices.

For insurers, the implications are immediate and profound. Traditional cannabis coverage has focused on product contamination, labeling errors, and bodily‑injury exposures, often relying on broad health‑hazard exclusions to limit liability. Murray v. Cresco introduces a new class of risk—deceptive marketing and failure‑to‑warn claims—that may fall outside those exclusions, especially where policies lack specific RICO or advertising‑injury carve‑outs. Underwriters must now scrutinize the scientific validity of health claims, the presence of warning labels, and the robustness of internal compliance programs. Policy language should be reviewed for gaps that could trigger coverage disputes under commercial general liability, products‑completed‑operations, and D&O policies.

The broader industry is likely to feel a ripple effect as the case proceeds. The DOJ’s recent rescheduling of state‑licensed cannabis to Schedule III signals growing federal legitimacy, but also raises expectations for product safety and truthful labeling. Canadian litigation history shows that once markets mature, consumer‑class actions become commonplace, and the U.S. appears poised to follow suit. Insurers and cannabis operators alike should adopt proactive risk‑mitigation strategies: conduct regular audits of marketing materials, align health claims with peer‑reviewed science, and embed clear, FDA‑style warnings. By treating marketing conduct as a front‑line exposure, the sector can better navigate the emerging legal landscape and protect both policyholders and insurers from catastrophic loss.